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Jennifer White, MS, a L. Kristin Newby, MD, a Michel Komajda, MD, b John McMurray, MD, c Robert Bigelow, PhD, a
Philip D. Home, DM, d and Renato D. Lopes, MD, PhD a Durham, NC; Paris, France; Glasgow, and Newcastle upon
Tyne, United KingdomBackground The US Food and Drug Administration (FDA) required a reevaluation of cardiovascular (CV) outcomes in
the RECORD trial. This provided an opportunity to assess the implications of event adjudication by 2 groups and quantify the
differences as well as to use new FDA end point definitions in development.
Methods Original data were used to systematically identify all potential deaths, myocardial infarctions (MIs), and strokes.
Site investigators were approached for additional source documents and information about participants lost to follow-up.
Suspected events were adjudicated using standard procedures, and the results were compared with the original trial outcomes.
Results Follow-up for mortality was 25,833 person-years, including an additional 328 person-years identified during the
reevaluation effort. A total of 184 CV or unknown-cause deaths (88 rosiglitazone, 96 metformin/sulfonylurea), 128
participants with an MI (68 rosiglitazone, 60 metformin/sulfonylurea), and 113 participants with a stroke (50 rosiglitazone,
63 metformin/sulfonylurea) were included. The hazard ratio (HR) for rosiglitazone versus metformin/sulfonylurea for the end
point of CV (or unknown cause) death, MI, or stroke was 0.95 (95% CI 0.78-1.17) compared with 0.93 (95% CI 0.74-1.15)
for the original RECORD results. Treatment comparisons for MI (HR 1.13, 95% CI 0.80-1.59) and mortality (HR 0.86, 95% CI
0.68-1.08) were also the same compared with the original RECORD results. Sensitivity analyses were also consistent with the
original RECORD results. Analyses using the FDA definitions showed similar results.
Conclusions Only a modest number of additional person-years of follow-up were ascertained from this reevaluation of
CV end points in RECORD. Observed HRs and CIs from these analyses using the original RECORD or new FDA end point
definitions showed similar treatment effects of rosiglitazone compared with the original RECORD results. (Am Heart J
2013;166:240-249.e1.)The cardiovascular (CV) safety of rosiglitazone therapy
has been debated for the past 5 years following the
publication of a systematic overview of nonadjudicated
data from diverse short-term studies suggesting that
rosiglitazone was associated with increased risk of
myocardial infarction (MI).1 Results from the RECORD
trial (ClinicalTrials.gov, NCT00379769)2,3 suggested
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Ometformin or a sulfonylurea for the primary composite
end point of CV death or CV hospitalization; however,
an increased risk of MI with rosiglitazone could not be
ruled out.
Review by a US Food and Drug Administration (FDA)
Advisory Committee4 noted concerns with RECORD,
including a low event rate potentially related to inadequate
ascertainment and processing of events in an open-label
trial. The FDA required that the trial sponsor, Glaxo-
SmithKline, commission a reevaluation of all deaths and
specific major CV end points (MIs and strokes). The Duke
Clinical Research Institute (DCRI) was contracted to
perform the work. All raw participant-level data sources
were to be provided to the DCRI team. The FDA requested
the original RECORD end point definitions and contem-
porary definitions under development by the FDA
Standardized Data Collection for Cardiovascular Trials
Initiative be used.5
This reevaluation of the RECORD trial end points
provided an opportunity to make a direct comparison
between the treatment effects of rosiglitazone determined
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trial with N25,000 person-years of exposure. It also
provided an opportunity to assess the application of the
new draft FDA end point definitions.Methods
Study conduct, event ascertainment, and adjudication
Details of the RECORD study have been published previous-
ly.2,6,7 In the original RECORD clinical events classification (CEC)
effort, all deaths and hospitalizations events were to be reported
by site investigators using standard paper case report form
modules; this was aided by local monitoring visits and screening
of serious adverse event reports. Data were collated and quality
checked by a commercial research organization (Quintiles,
Dublin, Ireland), which also prepared blinded event files and
submitted them for independent review by 2 physicians on a
Clinical Endpoints Committee. Disagreements between the 2
physician reviews were resolved by consensus of the group.
The detailed procedures used in the reevaluation effort are
described separately.8 In brief, DCRI personnel were to be
provided access to the original participant-level data, coordi-
nated efforts to acquire further source documentation from
the sites, collaborated with the sponsor and a third-party
vendor to obtain vital status on participants previously lost to
follow-up, developed the procedures to systematically identify
and adjudicate all potential endpoint events, and created
processes to redact information about assigned study drug
from study documents.
The identification of deaths, suspected MIs, and suspected
strokes was accomplished by creating a computer program that
scanned the electronic data provided by GlaxoSmithKline to the
DCRI. The computer algorithm identified data fields that
indicated a potential event may have occurred. The DCRI CEC
clinical personnel also performed manual reviews of the case
report form, including free text narratives, to identify possible
events. All deaths, all suspected MIs, and all suspected stroke
events were processed for adjudication. This differed from the
original RECORD CEC effort, in which only deaths and
hospitalizations that occurred during the CV follow-up were
reviewed by physicians. The physicians performing the event
adjudication for the original RECORD CEC and the DCRI CEC
work were experienced clinical trialists and had cardiology or
neurology expertise. The DCRI CEC used a similar review
process as the original RECORD CEC with an initial independent
review by 2 physicians. If these physicians disagreed, the event
was reviewed by a committee of at least 3 physicians, with final
determination by consensus.
Each potential event identified by DCRI procedures was
adjudicated using the original RECORD end point definitions for
cause of death, MI, and stroke, to be consistent with the original
RECORD trial. In addition, the draft definitions from the FDA
Standardized Data Collection for Cardiovascular Trials Initiative
were used to apply a contemporary set of definitions.5 The DCRI
physicians were also asked to assess subjectively whether
sufficient or insufficient information was available to adjudicate
the event using contemporary standards.
After completion of all adjudications, unblinding of the results,
and presentation of the final DCRI-prepared summary of the
findings to the sponsor and the FDA, discrepancies in anydecision for events reviewed by both the DCRI CEC and the
original RECORD CEC were reviewed together by members of
the DCRI team and members of the RECORD Steering
Committee. The events were evaluated, and reasons for
differences were identified. No changes to the event results by
the DCRI CEC or the original RECORD CEC groups occurred.
The DCRI Operational Team members, original RECORD CEC
and DCRI CEC physicians, and the sponsor partner representa-
tives are listed in the online Appendix.Statistical analyses
For the current analyses, differences between the rosiglita-
zone group and the control group were estimated as hazard
ratios (HRs) (with 95% CI) based on Cox proportional hazards
regression stratified for background medication. The primary
composite end point for the analyses in this article was the first
occurrence of CV (or unknown cause) death, MI, or stroke
occurring on or before December 31, 2008.7 The DCRI chose
this cutoff date because final study visits were to be conducted
between August and December 2008. Secondary end points
were overall mortality, CV or unknown cause death, MI, and
stroke. Analyses presented in this article informally tested the
null hypothesis of equality between the rosiglitazone and
metformin/sulfonylurea treatment arms by claiming significance
if the 95% CI for the HR excluded 1.0. The RECORD trial was
originally designed as a noninferiority trial, with a margin of 1.20
for the end point of CV hospitalization or death; however, we
analyzed a different primary end point (CV death, MI, or stroke)
and did not make conclusions regarding noninferiority.
The original RECORD CEC adjudicated all deaths and CV
hospitalizations occurring up to the final study visit or
withdrawal of consent. Per protocol, the original CEC did not
process and adjudicate any deaths or nonfatal events occurring
to a patient after the patient had withdrawn from the CV follow-
up phase of the study and was being followed up for vital status
only. With the exception of deaths, which were included in the
all-cause mortality analysis, events observed in the vital status
only follow-up period were neither collected nor reported in the
original RECORD analysis.
The DCRI CEC adjudicated all deaths and nonfatal MI and
stroke events occurring up to the end of the study (December
31, 2008). Follow-up for participants who did not experience
MI, stroke, or CV death was based on the date of the last face-to-
face study visit. Therefore, analyses performed by the DCRI
group of CV outcomes and their components include identified
events that were not included in the original RECORD analyses
due to different analytic approaches. To support time-to-event
analyses of study end points, DCRI derived follow-up periods
for each participant, using all available study documentation.
Analyses were also performed for the components of the CV
death, MI, or stroke composite end point and for all-cause
mortality. Sensitivity analyses were performed to test the
robustness of the results for all-cause mortality; the primary
end point; and the components CV death, MI, and stroke. These
analyses included on-treatment analyses (censoring at 30 days
after last study drug treatment), landmark analyses up to and
following the date of a protocol amendment that instituted a
tracking substudy to collect data from patients who had
withdrawn (February 27, 2006), landmark analyses up to and
following the date of the publication of the RECORD interim
Table I. Treatment comparisons using the DCRI CEC results and the original RECORD CEC results using the original RECORD end point definitions
Rosiglitazone Metformin/sulfonylurea HR (95% CI)
DCRI CEC results (original definitions)
CV (or unknown cause) death, MI, or stroke 181 (8.3%) 188 (8.4%) 0.95 (0.78-1.17)
CV (or unknown cause) death 88 (4.0%) 96 (4.3%) 0.90 (0.68-1.21)
MI 68 (3.1%) 60 (2.7%) 1.13 (0.80-1.59)
Stroke 50 (2.3%) 63 (2.8%) 0.79 (0.54-1.14)
All death 139 (6.3%) 160 (7.2%) 0.86 (0.68-1.08)
Original RECORD CEC results (original definitions)
CV (or unknown cause) death, MI, or stroke 154 (6.9%) 165 (7.4%) 0.93 (0.74-1.15)
CV (or unknown cause) death 60 (2.7%) 71 (3.2%) 0.84 (0.59-1.18)
MI 64 (2.9%) 56 (2.5%) 1.14 (0.80-1.63)
Stroke 46 (2.1%) 63 (2.8%) 0.72 (0.49-1.06)
All death 136 (6.1%) 157 (7.0%) 0.86 (0.68-1.08)
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completion date (August 24, 2008). An additional sensitivity
analysis included only events for which adjudicators reported
that there was sufficient information for classification.
Differences in the number of deaths, MIs, or strokes reported
by the original RECORD CEC and the DCRI CEC are provided.
Role of the funding source
The sponsor of the studywas GlaxoSmithKline (King of Prussia,
PA). The role of the sponsor in the conduct of the study has been
published previously.7 Funding for the reevaluation effort was
provided to DCRI. The sponsor FDA personnel and members of
the RECORD Steering Committee reviewed and commented on
the protocol before any work was performed. The DCRI and
RECORD Steering Committee representatives made the decision
to publish the findings and have written the manuscript jointly.
The manuscript and clinical study reports were reviewed by
sponsor representatives for accuracy. The sponsor facilitated and
enabled access for DCRI personnel to all trial data.Results
Additional follow-up and events identified
Follow-up for mortality was 25,833 person-years,
including an additional 328 person-years identified during
the reevaluation effort from participants with incomplete
vital status at the end of the original RECORD study.
Follow-up for the CV death, MI, or stroke composite was
23,692 person-years because participants without an
event were censored on the date of the last face-to-face
study visit. Vital status follow-up was complete for 96.0%
of the participants (96.7% and 95.4% in the rosiglitazone
and metformin/sulfonylurea groups, respectively). For
the CV death, MI, or stroke composite end point, follow-
up was complete for 83.3% of the participants (84.5% and
82.1% in the rosiglitazone and metformin/sulfonylurea
groups, respectively).
DCRI CEC metrics
Querying of the original RECORD database identified
314 deaths, 2,101 suspected MIs, and 496 suspectedstrokes. Of these, the computer program screening the
database identified 2,052 suspected MIs and 468
suspected strokes, and manual review of documents by
DCRI CEC coordinators identified an additional 49
suspected MIs and 28 suspected strokes. Of the 2,911
suspected events identified, 701 nonfatal events were not
processed because they were duplicate events or no
indication of an event was identified upon further
processing. The remaining 314 deaths, 1,474 suspected
MIs, and 422 suspected strokes were processed and
adjudicated by the DCRI CEC clinicians.
Clinical outcomes
Table I shows the CV death, MI, and stroke outcomes
using the DCRI CEC results and the original RECORD
CEC results by treatment using the original RECORD
end point definitions.7 Figure 1 shows Kaplan-Meier
curves for the primary composite outcome using DCRI
CEC results and the original RECORD end point
definitions. A total of 184 CV or unknown cause
deaths (88 rosiglitazone, 96 metformin/sulfonylurea),
137 MIs in 128 participants (68 rosiglitazone, 60
metformin/sulfonylurea), and 119 strokes in 113
participants (50 rosiglitazone, 63 metformin/sulfonyl-
urea) were identified by the DCRI CEC efforts using the
same end point definitions as used in the original
RECORD CEC. For the primary end point—time to first
occurrence of CV (or unknown cause) death, MI, or
stroke—no statistically significant difference was ob-
served between rosiglitazone and metformin/sulfonyl-
urea using the original RECORD end point definitions
(HR 0.95, 95% CI 0.78-1.17). These results were
comparable with those reported in the original
RECORD study (HR 0.93, 95% CI 0.74-1.15). Cardiovas-
cular (or unknown cause) death was similar between
rosiglitazone and metformin/sulfonylurea using the
original RECORD end point definitions (HR 0.90, 95%
CI 0.68-1.21). For time to first fatal and nonfatal MI and
for time to first fatal and nonfatal stroke, the
comparisons between rosiglitazone and metformin/
Figure 1
Kaplan-Meier curves for the primary composite end point using the DCRI CEC results and the original RECORD end point definitions.
Table II. The DCRI CEC outcomes by randomized treatment comparison using the original RECORD end point definitions and new FDA end
point definitions
Rosiglitazone Metformin/sulfonylurea HR (95% CI)
DCRI CEC results—original RECORD end point definitions
CV (or unknown cause) death, MI, or stroke 181 (8.3%) 188 (8.4%) 0.95 (0.78-1.17)
Death—all cause 139 (6.3%) 160 (7.2%) 0.86 (0.68-1.08)
CV (or unknown cause) death 88 (4.0%) 96 (4.3%) 0.90 (0.68-1.21)
MI 68 (3.1%) 60 (2.7%) 1.13 (0.80-1.59)
Stroke 50 (2.3%) 63 (2.8%) 0.79 (0.54-1.14)
DCRI CEC results—new FDA end point definitions
CV (or unknown cause) death, MI, or stroke 186 (8.4%) 191 (8.6%) 0.97 (0.79-1.18)
Death—all cause 139 (6.3%) 160 (7.2%) 0.86 (0.68-1.08)
CV (or unknown cause) death 88 (4.0%) 96 (4.3%) 0.90 (0.68-1.21)
MI 72 (3.2%) 62 (2.8%) 1.15 (0.82-1.62)
Stroke 53 (2.4%) 64 (2.9%) 0.82 (0.57-1.18)
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1.59 and HR of 0.79 and 95% CI of 0.54 to 1.14,
respectively.
The HR for all-cause mortality was the same using the
DCRI CEC and original RECORD CEC results (0.86, 95% CI
0.68-1.08).Original end point definitions compared with
FDA definitions
Table II shows composite CV death, MI, and stroke
outcomes and the contribution of each event to the
composite from the DCRI CEC results using the
original RECORD end point definitions and the new
FDA definitions. Figure 2 shows the Kaplan-Meier
curves for the CV death, MI, and stroke compositeend point using the DCRI CEC results and the new
FDA definitions. The event rates and treatment
comparisons are similar using the original RECORD
end point definitions and the new FDA end point
definitions. A comparison at the event level rather
than the patient level (as in Table II) of the cause of
death adjudications, number of MIs, and number of
strokes using the original RECORD end point
definitions and the new FDA end point definitions
is shown in Table III. The results of cause of death
adjudication were the same using both sets of
definitions. The use of the new FDA end point
definitions resulted in a small number of additional
stroke (4) and MI (14) events primarily because the
new FDA end point definitions for MI or stroke do
not require hospitalization.
Figure 2
Kaplan-Meier curves for the primary composite end point using the DCRI CEC results and the new FDA end point definitions.
Table III. Comparison of DCRI CEC results using original
RECORD end point definitions and new FDA end point
definitions where either definition delivered a confirmed event
Original RECORD
end point
definitions
New FDA end point definitions
CV
death
Non-CV
death
Unknown
cause death
CV death 77 0 0
Non-CV death 0 117 0
Unknown cause death 0 0 120
MI No MI
No MI 14 –
MI 137 0
Stroke No stroke
No stroke 4 –
Stroke 119 0
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Table IV shows the results of a series of sensitivity
analyses using the DCRI CEC results with the new FDA
end point definitions. In the on-treatment analyses and
landmark analyses attempting to account for potential
bias after the interim publication, no evidence of
heterogeneity in treatment effect was observed com-
pared with the overall DCRI CEC results. Additional
analyses using data acquired before amendment 7 or
using an end date of the earliest possible final study visit
showed similar results (data not shown).
Of the events adjudicated by the DCRI CEC group using
the new FDA definitions, 45.5% of all deaths, 78.1% of
MIs, and 94.3% of strokes were determined to have
sufficient information by the CEC physicians. Results of
the analyses of only those events with sufficient
information were consistent with the analyses for the
composite of CV death, MI, and stroke and the individual
components using the DCRI CEC results.
Comparison of the original RECORD CEC and the DCRI
CEC results
Figure 3 details the death reporting of the original
RECORD CEC analysis and the DCRI CEC analysis. One
participant was reported dead in the original data set,
but the DCRI CEC group did not believe that there was
enough evidence to confirm that the participant died. In
total, the DCRI CEC group identified 20 deaths not
reported in the original RECORD report. Of these 20,
8 (5 rosiglitazone and 3 metformin/sulfonylurea) oc-
curred before the DCRI-defined final follow-up of
December 31, 2008, and 12 (7 rosiglitazone and 5metformin/sulfonylurea) occurred after this date. Of the
8 deaths occurring before December 31, 2008, 4
occurred before the end of the original RECORD-
defined final follow-up. Seven of the deaths occurred
during the additional 328 person-years of follow-up
obtained during the reevaluation effort.
Overall, the DCRI CEC effort reported more CV or
unknown deaths (184 vs 131), more MI events (128 vs
Table IV. Treatment comparisons from sensitivity analyses using the DCRI CEC results and the new FDA end point definitions
Subgroup End point
Rosiglitazone,
n = 2220
Metformin/sulfonylurea,
n = 2227 HR (95% CI)
On study treatment +30 d
CV (or unknown cause) mortality, MI, and stroke 128 129 0.94 (0.73-1.20)
All-cause mortality 57 70 0.76 (0.54-1.08)
CV (or unknown cause) death 34 43 0.74 (0.47-1.16)
MI (fatal and nonfatal) 63 51 1.17 (0.81-1.70)
Stroke (fatal and nonfatal) 42 52 0.76 (0.51-1.14)
Up to publication of interim report
CV (or unknown cause) mortality, MI, and stroke 142 150 0.95 (0.75-1.19)
All-cause mortality 97 114 0.84 (0.64-1.10)
CV (or unknown cause) death 55 68 0.80 (0.56-1.14)
MI (fatal and nonfatal) 59 53 1.11 (0.77-1.61)
Stroke (fatal and nonfatal) 45 49 0.92 (0.61-1.37)
Only end points with sufficient information for classification
CV (or unknown cause) mortality, MI, and stroke 124 122 1.01 (0.79-1.30)
MI (fatal and nonfatal) 56 51 1.09 (0.75-1.60)
Stroke (fatal and nonfatal) 52 59 0.87 (0.60-1.27)
Figure 3
Deaths reported by the DCRI CEC and original RECORD CEC and reasons for differences.
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original RECORD CEC process. Although numbers of all-
cause deaths increased modestly with the DCRI CEC
effort, the proportion of deaths classified as CV death
by the DCRI CEC, which included deaths of unknown
cause, was notably higher (see Table I). Most of thiswas explained by the DCRI CEC group adjudicating
deaths with little information or deaths in participants
with known cancer but no details about cancer
progression available in the months before reported
death as unknown cause because patients with cancer
may die of many reasons besides cancer; these deaths
Figure 4
Agreements and disagreements in the classification of cause of death between the original RECORD CEC and the DCRI CEC.
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as specified in the DCRI and original RECORD analytic
plans. Because the original RECORD CEC reported
these as non-CV death, they were not included in the
CV cause of death analyses.
Figure 4 shows the agreements and disagreements in
the classification of cause of death for the 251 events
adjudicated by both the original RECORD CEC and the
DCRI CEC using the original RECORD cause of death
end point definitions. Overall, there was agreement for
199 (79%) and disagreement for 52 (21%).
It was not possible to determine the total number
of agreements or disagreements between the 2 CEC
groups for MI or stroke because the original RECORD
CEC reviewed only hospitalizations to identify MI and
stroke events, whereas the DCRI CEC reviewed any
suspected MI and stroke events. However, 14 MI
events were reported by either the original RECORD
CEC or the DCRI CEC but not both. Of these 14
MI events, 11 (5 rosiglitazone and 6 metformin/
sulfonylurea) were reported by the DCRI CEC, and 3
(1 rosiglitazone and 2 metformin/sulfonylurea) by the
original RECORD CEC. In total, 18 stroke events were
reported by either the original RECORD CEC or the
DCRI CEC but not both. Of these 18 stroke events,
11 (7 rosiglitazone and 4 metformin/sulfonylurea)
were reported by the DCRI CEC, and 7 (3 rosiglita-zone and 4 metformin/sulfonylurea) by the original
RECORD CEC.Discussion
A comprehensive reevaluation of all deaths and all
suspected MI and stroke events was performed by an
academic group (DCRI CEC) using the raw RECORD data.
For the primary end point of these analyses—time to first
occurrence of a composite of CV or unknown death, MI,
or stroke—no meaningful difference between rosiglita-
zone and metformin/sulfonylurea was observed using the
original RECORD end point definitions (HR 0.95, 95% CI
0.78-1.17) or new FDA end point definitions (HR 0.97,
95% CI 0.79-1.18). Furthermore, these results are similar
to results from the original RECORD study (HR 0.93, 95%
CI 0.74-1.15). The original RECORD study results and the
DCRI CEC results were also similar for the individual
components of the composite end point. These findings
and the additional sensitivity analyses performed support
the original RECORD results and suggest that when using
essentially the same data, the observations were not
affected by different CEC processes, physician adjudica-
tors, or end point definitions.
Two key operational objectives of the DCRI CEC
reevaluation effort were to obtain more information in
patients lost to follow-up and to identify potentially
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effort to obtain additional information, only a modest
amount of additional person-years of follow-up was
obtained (328 person-years). Multiple challenges were
realized, including many clinical sites with disbanded
research groups, inability to obtain institutional review
board approval, and regulations in some countries that
would not allow access to databases or clinical records.
Systematic querying of the original RECORD database and
the modest additional follow-up information added only a
small number of additional nonfatal events (11 MIs and 11
strokes) and removed a few (3 MIs and 7 strokes).
RECORD was designed as an open-label trial and used
a blinded CEC group to adjudicate clinical events. A
similar strategy has been used in other large outcome
trials. A concern about biased ascertainment of the end
point events during the original RECORD trial has been
suggested by some individuals, including improper
processing of some events that had been reported.4
The processes used by the DCRI CEC group to identify
all possible events and obtain additional follow-up, the
statistical analyses including landmark analyses to
evaluate potential influence of amendments and publi-
cation of interim analyses, and the application of the
new FDA end point definitions did not find evidence of
systematic bias in processing of events reported by the
site investigators. In addition, the overall rate of MI
using the DCRI CEC results and the original RECORD
end point definition (0.54 per 100 person-years or 2.9%)
appears consistent with CV outcomes reported in recent
systematic reviews,9 although the populations, study
designs, follow-up, event definitions, and ascertainment
varied.10-27
A comparison of differences in the classification of
cause of death and occurrence of the nonfatal end points
between 2 experienced CEC groups showed that the
DCRI CEC group identified more CV outcomes using the
same end point definitions as the original RECORD CEC.
This was primarily because the DCRI CEC attributed more
deaths (184 vs 131) to a CV or unknown cause compared
with the RECORD CEC. One reason for this was that the
RECORD CEC attributed some deaths to cancer, whereas
the DCRI CEC classified these same deaths as unknown (n
= 17). This discrepancy arose mainly because participants
with a diagnosis of cancer who later died were often
adjudicated as non-CV deaths by the RECORD CEC,
whereas if no follow-up had taken place for a significant
period before the participant's death, the DCRI CEC
tended to classify the cause as unknown. Although only a
modest number of additional MI events (n = 8) and stroke
events (n = 4) were identified, they were balanced across
treatment groups. These findings, along with the
consistent overall results, support lack of obvious
systematic concerns in adjudication after review by
both CEC groups. Similar findings have been reported
previously and highlight that limited data from the studysites and the lack of conventions for the application of
standard definitions can make end point adjudication
difficult and subject to disagreement.28-31 There is
confidence that all the events reported by the site
investigators were identified and processed. The number
of events that may not have been reported by the site
coordinators or investigators is unknown and is a
potential limitation in all clinical trials.
The use of the new FDA end point definitions for cause
of death, MI, and stroke provided the first opportunity to
apply these definitions in a large CEC effort. The results
from the DCRI CEC effort using the original RECORD and
the new FDA definitions were similar. The new FDA end
point definitions allow classification of MI or stroke based
on outpatient evaluations or in patients who died out of
hospital. Although controversy exists over specific
criteria to use for end point definitions, the comparison
of DCRI CEC results using 2 different definitions does not
support one definition over another. However, it is clear
that standard definitions are needed for consistency in
drug development programs and for comparison of event
rates between trials.
The HR and 95% CI for MI with rosiglitazone compared
with metformin/sulfonylurea were similar using the
original RECORD trial data or using the DCRI CEC results
with either the original RECORD or the new FDA end
point definitions. Potential for a nearly 59% to 63%
increase in risk or an 18% to 22% benefit cannot be
excluded. However, the RECORD trial was not powered
for a comparison on any of the individual components of
the primary composite. Systematic reviews have reported
a statistically significant increase in MI associated with
rosiglitazone, although such analyses have well-known
limitations. The definitive approach to understand the
potential hazard of MI with rosiglitazone is a large,
double-blind, randomized clinical trial. The TIDE trial
with rosiglitazone was evaluating CV outcomes but has
been put on full clinical hold by the FDA (http://
clinicaltrials.gov/ct2/show/NCT00879970).Limitations
This retrospective reevaluation effort has important
limitations. First, it relied heavily on the original RECORD
database and source documentation because only a
modest amount of additional follow-up was obtained,
and most of the additional information obtained was
about vital status and not nonfatal MIs or strokes. Second,
using contemporary standards, it was determined that
35% of the events reviewed had a subjective assessment
of insufficient information to make a confident decision.
However, analyses with only events that had sufficient
information had similar results. Finally, the entire CEC
group was blinded to treatment assignment, but we had
no mechanism to overcome other potential biases
introduced by the open-label trial design.
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The reevaluation of RECORD CV outcomes included a
blinded systematic review of the original RECORD
database and study documents supplemented by an
attempt to contact study investigators for additional
participant follow-up information. Because of logistical
challenges, only a modest number of additional person-
years of information were obtained compared with the
initial RECORD data. The results of this reevaluation and
analyses provide several key findings. First, results using
the DCRI CEC data including extensive sensitivity analyses
were consistent with the originally published RECORD
results and did not show statistically significant differences
between the rosiglitazone and the metformin/sulfonylurea
groups for the composite end point of CV death, MI, or
stroke and the individual components. Second, a compar-
ison of event adjudication by 2 CEC groups using the same
end point definitions showed only a small increase in the
number of stroke or MI events reported by the DCRI CEC
group compared with the original RECORD CEC group.
The DCRI CEC group adjudicated more deaths as CV
deaths because physicians were more likely to adjudicate
the cause of death as unknown rather than non-CV cause
when limited information was available and deaths with
unknown cause were included in the CV death analyses
per protocol. Third and finally, comparative treatment
results were similar using a contemporary set of end point
definitions being developed by the FDA compared with
the historical definitions.
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